For those aiming to surpass market returns, the art of stock picking is crucial. Making wise choices in stocks can greatly enhance your overall wealth.
After finishing at $3.79 in the prior trading day, Cytek BioSciences Inc (NASDAQ: CTKB) closed at $2.92, down -22.82%. In other words, the price has decreased by -$22.82 from its previous closing price. On the day, 2.22 million shares were traded.
Ratios:
Our goal is to gain a better understanding of CTKB by taking a closer look at its different ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 1.41 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 21.34. For the most recent quarter (mrq), Quick Ratio is recorded 4.95 and its Current Ratio is at 5.62. In the meantime, Its Debt-to-Equity ratio is 0.07 whereas as Long-Term Debt/Eq ratio is at 0.05.
On January 31, 2025, Goldman Downgraded its rating to Sell which previously was Buy and also lowered its target price recommendation from $7 to $4.50.
On December 14, 2023, Stephens started tracking the stock assigning a Overweight rating and target price of $9.Stephens initiated its Overweight rating on December 14, 2023, with a $9 target price.
Valuation Measures:
For the stock, the TTM Price-to-Sale (P/S) ratio is 1.89 while its Price-to-Book (P/B) ratio in mrq is 0.98.
Stock Price History:
Over the past 52 weeks, CTKB has reached a high of $7.63, while it has fallen to a 52-week low of $3.27. The 50-Day Moving Average of the stock is -25.80%, while the 200-Day Moving Average is calculated to be -44.92%.
Shares Statistics:
A total of 127.60M shares are outstanding, with a floating share count of 114.78M. Insiders hold about 9.38% of the company’s shares, while institutions hold 59.26% stake in the company.
